semaglutide weekly Day 2: Wegovy (Semaglutide 2.4 mg injection) Class: GLP-1 receptor agonist Avg Weight Loss: ~15% of baseline weight Dosing: Weekly subcutaneous injection FDA Approved: June 2021 for chronic weight management Pros Injectable Semaglutide - Weekly GLP-1

Ipamorelin generally has a milder side effect profile than synthetic HGH

This leads to lower calorie intake and sustainable weight loss when paired with healthy habits and medical supervision

The combined effect of the two medications often allows patients to achieve more consistent weight reduction with fewer fluctuations in daily eating patterns

it rewrites your biology

both drugs are made by Eli Lilly, and the company has positioned them as complementary rather than competitive: tirzepatide for patients needing maximum weight loss, and orforglipron for patients preferring oral therapy or as a maintenance option after injectable treatment

At 2 mg, mild queasiness may occur